[go: up one dir, main page]

NO20092382L - Radioaktivt diagnostiserende avbildningsmiddel - Google Patents

Radioaktivt diagnostiserende avbildningsmiddel

Info

Publication number
NO20092382L
NO20092382L NO20092382A NO20092382A NO20092382L NO 20092382 L NO20092382 L NO 20092382L NO 20092382 A NO20092382 A NO 20092382A NO 20092382 A NO20092382 A NO 20092382A NO 20092382 L NO20092382 L NO 20092382L
Authority
NO
Norway
Prior art keywords
radiolysis
imaging agent
diagnostic imaging
sugar
radioactive diagnostic
Prior art date
Application number
NO20092382A
Other languages
English (en)
Other versions
NO343137B1 (no
Inventor
Masahito Toyama
Akio Hayashi
Daisaku Nakamura
Toshiyuki Shinmura
Emi Kaneko
Soichi Nakamura
Shinji Tokunaga
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of NO20092382L publication Critical patent/NO20092382L/no
Publication of NO343137B1 publication Critical patent/NO343137B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

En sammensetning som innbefatter en radioaktiv fluormerket aminosyreforbindelse er tilveiebrakt, som kan hindres fra radiolyse. Beskrevet er en sammensetning som innbefatter en løsning som inneholder en radioaktiv fluormerket aminosyreforbindelse som en effektiv ingrediens, hvori pH-verdien til løsningen holdes ved 2,0-5,9, mer foretrukket 2,0-4,9 for å inhibere radiolyse. I tillegg er det mulig ytterligere å inhibere radiolyse ved tilsetting dertil av et farmasøytisk additiv i stand til å inhibere radiolyse, slik som et sukker, en sukkeralkohol og et sukkerlakton, mens pH holdes ved 2,5-5,9.
NO20092382A 2006-12-21 2009-06-23 Radioaktivt diagnostisk avbildningsmiddel NO343137B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006343753 2006-12-21
PCT/JP2007/072444 WO2008075522A1 (ja) 2006-12-21 2007-11-20 放射性画像診断剤

Publications (2)

Publication Number Publication Date
NO20092382L true NO20092382L (no) 2009-09-16
NO343137B1 NO343137B1 (no) 2018-11-19

Family

ID=39536156

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092382A NO343137B1 (no) 2006-12-21 2009-06-23 Radioaktivt diagnostisk avbildningsmiddel

Country Status (15)

Country Link
US (1) US8790620B2 (no)
EP (1) EP2106808B1 (no)
JP (1) JP5159636B2 (no)
KR (2) KR101579796B1 (no)
CN (1) CN101563107B (no)
AU (1) AU2007335633A1 (no)
BR (1) BRPI0721157A2 (no)
CA (1) CA2672262C (no)
ES (1) ES2663696T3 (no)
NO (1) NO343137B1 (no)
PL (1) PL2106808T3 (no)
PT (1) PT2106808T (no)
RU (1) RU2445120C2 (no)
TW (1) TWI409083B (no)
WO (1) WO2008075522A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1978015T3 (pl) 2005-11-29 2018-07-31 Nihon Medi-Physics Co., Ltd. Związek prekursorowy związku organicznego znakowanego radioaktywnym halogenem
KR101485445B1 (ko) 2007-02-13 2015-01-22 니혼 메디피직스 가부시키가이샤 방사성 화상진단제의 제조 방법
JP6018581B2 (ja) 2010-12-29 2016-11-02 ジーイー・ヘルスケア・リミテッド 溶出溶液
GB201411569D0 (en) 2014-06-30 2014-08-13 Ge Healthcare Ltd Novel formulation and method of synthesis
AU2012356846B2 (en) * 2011-12-21 2017-07-27 Ge Healthcare Limited 18F - Fluciclovine compositions in citrate buffers
US11534494B2 (en) 2011-12-21 2022-12-27 Ge Healthcare Limited Formulation and method of synthesis
GB201305687D0 (en) 2013-03-28 2013-05-15 Ge Healthcare Ltd Radiolabelling process

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2756593B2 (ja) 1989-09-01 1998-05-25 日本鋼管株式会社 地中掘削装置
JPH0443497A (ja) 1990-06-09 1992-02-13 Omron Corp 多車線対応型車両感知器
JPH0456725A (ja) 1990-06-26 1992-02-24 Sumitomo Metal Ind Ltd 加工性に優れた熱延鋼板の製造方法
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
JP2000510816A (ja) * 1995-10-17 2000-08-22 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２の検出法
US6027710A (en) 1996-09-18 2000-02-22 Nihon Medi-Physiscs Co., Ltd. Radiation-protecting agent
JP4242465B2 (ja) 1996-09-18 2009-03-25 日本メジフィジックス株式会社 放射線防護剤
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6017706A (en) * 1997-05-07 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Process for identifying compounds which protect against the formation of fluorescent light induced DNA lesions and x-ray-induced lesions
BR0207315A (pt) * 2001-02-26 2004-02-10 Bristol Myers Squibb Pharma Co Análogos de ácido ascórbico para metalorradiofármacos
EP1356827A1 (en) * 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
JP2006505610A (ja) 2002-11-05 2006-02-16 イヨン ベアム アプリカスィヨン エッス．アー． １８−ｆ標識放射性製剤の安定化
KR100508518B1 (ko) 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
GB0229695D0 (en) * 2002-12-20 2003-01-29 Amersham Plc Solid-phase preparation of 18F-labelled amino acids
GB0422004D0 (en) 2004-10-05 2004-11-03 Amersham Plc Method of deprotection
ES2364463T3 (es) * 2005-05-23 2011-09-02 Nihon Medi-Physics Co., Ltd. Nuevo compuesto orgánico, y método para producir un compuesto orgánico marcado con halógeno radioactivo que usa el mismo.
CA2612187C (en) * 2005-06-23 2013-05-07 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
KR101485445B1 (ko) 2007-02-13 2015-01-22 니혼 메디피직스 가부시키가이샤 방사성 화상진단제의 제조 방법

Also Published As

Publication number Publication date
KR101497406B1 (ko) 2015-03-02
US20100028258A1 (en) 2010-02-04
NO343137B1 (no) 2018-11-19
PT2106808T (pt) 2018-03-26
RU2445120C2 (ru) 2012-03-20
EP2106808B1 (en) 2018-02-21
AU2007335633A1 (en) 2008-06-26
BRPI0721157A2 (pt) 2014-04-01
HK1134901A1 (en) 2010-05-20
TWI409083B (zh) 2013-09-21
JPWO2008075522A1 (ja) 2010-04-08
US8790620B2 (en) 2014-07-29
PL2106808T3 (pl) 2018-07-31
CA2672262A1 (en) 2008-06-26
CN101563107A (zh) 2009-10-21
EP2106808A1 (en) 2009-10-07
KR20090094081A (ko) 2009-09-03
CA2672262C (en) 2016-07-05
TW200826964A (en) 2008-07-01
KR20150004940A (ko) 2015-01-13
WO2008075522A1 (ja) 2008-06-26
EP2106808A4 (en) 2013-02-27
JP5159636B2 (ja) 2013-03-06
RU2009128055A (ru) 2011-01-27
KR101579796B1 (ko) 2015-12-24
ES2663696T3 (es) 2018-04-16
CN101563107B (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
NO20092382L (no) Radioaktivt diagnostiserende avbildningsmiddel
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
BR112012003592B8 (pt) composição farmacêutica contendo derivado de quinolina
BR112012018384A2 (pt) composição farmacêutica sólida com intensificadores e métodos de preparação da mesma.
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
UA109774C2 (uk) Кристалічні форми саксагліптину та процес його одержання (варіанти)
CL2011001924A1 (es) Compuestos derivados de aminotetralina, inhibidores de glyt1; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso en el tratamiento de problemas neurologicos, psiquiatricos o dolor.
UY30649A1 (es) Compuestos de biaril éter urea
NO20062513L (no) Sammensetninger og doseringsformer for forsterket absorpsjon av metformin
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
BR112012021657A2 (pt) composto, agentes farmacêutico, agonístico de casr, e agente para conferir kokumi, e, temperos
WO2009007137A3 (en) Pharmaceutical composition for topical application of poorly soluble compounds
AU2015275248B2 (en) Legumain activated doxorubicin derivative as well as preparation method and application thereof
NO20084478L (no) Konjugerte lipidderivater
MX363417B (es) Composicion vaginal a base de poliglucosidos de alquilo.
AR069249A1 (es) Derivado de indazol, activo en el dolor neuropatico
BRPI0900482A2 (pt) composições para proporcionar um efeito analgésico à pele
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren
WO2009008461A1 (ja) 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物
Arvanitis et al. Mechanism of action of potent boron-containing antifungals
US20100173875A1 (en) Formulation of aspirin that is stable and showing minimal hydrolysis for parenteral adminstration for the treatment of cardiovascular and other disease states
RU2011134414A (ru) Комбинация фульвовой кислоты для лечения различных состояний и болезней